Compare Citius Pharmaceuticals Inc (CTXR) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs L3Harris Technologies Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while L3Harris Technologies Inc trades at $236.8 (market cap $44.12B). The key difference: L3Harris Technologies Inc is far larger — about 3239.4× Citius Pharmaceuticals Inc's market cap, and L3Harris Technologies Inc pays a 2.11% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and L3Harris Technologies Inc for 56 Days on average.
| CTXR | LHX | |
|---|---|---|
Market Cap | $13.62M | $44.12B |
Volume | 132,438 | 1,202,852 |
Sector | Health | Industrials |
52-Week High | $1.82 | $378.48 |
52-Week Low | $0.48 | $233.63 |
Typical Hold Time | 17 Days | 56 Days |
Enterprise Value | $3.79M | $54.56B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
LHX trades at $237.15, up 1.51% on the day, with a bearish technical signal from moving averages but strong fundamental performance, including three consecutive quarterly EPS beats. The company secured major defense contracts totaling over $10.7 billion in September 2026, supporting future revenue growth. Profit margins have improved steadily, with net income margin reaching 7.34% in 2025, and cash flow from operations strengthened to $3.11 billion.
The outlook is positive given robust contract wins and earnings momentum, but risks include ongoing legal investigations and high debt levels. Analyst consensus is strongly bullish with a $340 price target, implying significant upside from current levels, though technical indicators suggest near-term resistance around $238-$240.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
